



FOR: CARDIOCOMM SOLUTIONS, INC.

TSX VENTURE SYMBOL: EKG

CardioComm Solutions Issues Stock Options and Shares.

TORONTO, ONTARIO – December 28, 2012. [CardioComm Solutions, Inc.](#) (“CardioComm Solutions” or the “Company”) (TSX VENTURE:EKG), a global medical provider of ECG acquisition and management software solutions, today announced that an aggregate of 350,000 incentive stock options have been granted for services rendered in Q3 2012 in accordance with agreements with the Company; 250,000 options were granted to the CEO, Etienne Grima, and 100,000 options were granted to Simi Grosman, a member of the board of directors. The options are exercisable at \$0.27 per share for five years from the date of grant, vest equally over 18 months at the end of each three month period from the date of grant and are subject to a four month hold period. The grant of options is subject to the provisions of the Company’s Omnibus Share Compensation Plan, the policies of the TSX Venture Exchange and applicable securities laws.

In addition, the Company announced that it has settled \$15,000 of outstanding debt in exchange for the issuance of 30,000 common shares of the Company at a deemed price of \$0.50 per share. The debt represents accrued consulting fees for services provided to the Company ending December 2012. The shares for debt transaction is subject to the approval of the TSX Venture Exchange.

The Company also issued a correction respecting the amount raised in its previously announced private placement financing (for further details respecting the private placement, please see the Company’s press release dated March 20, 2012). Under the financing, the Company actually raised \$1.5 million through the issuance of 3,000,000 units, a reduction of \$50,000 from the previously announced amount.

About CardioComm Solutions

CardioComm Solutions’ patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software and HeartCheck™ devices. CardioComm Solutions, Inc. is headquartered in Toronto, Canada, with offices in Victoria, B.C.

FOR FURTHER INFORMATION PLEASE CONTACT:

Etienne Grima, Chief Executive Officer

1-877-977-9425 x227



**CardioComm
Solutions, Inc.**

PRESS RELEASE

egrima@cardiocommsolutions.com

www.cardiocommsolutions.com

Forward-looking statements

This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release